Established by TEDA Enterprise, Key Biomedical Laboratory in Tianjin Passes Acceptance Review

Recently, the Key Laboratory of Non-Clinical Evaluation of Biopharmaceuticals in Tianjin, led by Tianjin Yugen Medtech, passed its acceptance review. Since receiving approval for construction in December 2023, the laboratory has assembled a specialized technical team and equipped itself with world-leading instruments. It focuses on cutting-edge areas including pharmacodynamic evaluation of anti-tumor effects using PDO and PDX models for innovative biologics, preclinical evaluation of complex biologics, advanced therapy assessment, and nucleic acid drug preclinical evaluation. The laboratory has progressively built a technical research system covering major types of innovative biologics. To date, it has served over 300 biopharmaceutical companies on their innovative drug projects, undertaken more than 400 key research studies, and assisted drug R&D enterprises in obtaining 18 clinical trial approvals for biotech drugs.  

Yugen (Tianjin) Medtech Co., Ltd. is a CRO company that provides new drug R&D institutions and pharmaceutical enterprises at home and abroad with full-process, one-stop preclinical and clinical research technical services covering pharmacology, toxicology, and pharmacokinetic evaluation. Headquartered in TEDA, the company possesses a laboratory in the Pudong New Area of Shanghai.